AbbVie
ABBV
#26
Rank
NZ$691.65 B
Marketcap
NZ$391.34
Share price
-1.15%
Change (1 day)
34.26%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Total assets

Total assets on the balance sheet as of September 2025 : NZ$231.77 Billion

According to AbbVie's latest financial reports the company's total assets are NZ$231.77 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

AbbVie - Total assets on balance sheet (from 2011 to 2025)

Total assets by year

Year Total assets Change
2024-12-31NZ$239.65 B12.51%
2023-12-31NZ$213.01 B-2.57%
2022-12-31NZ$218.62 B1.91%
2021-12-31NZ$214.52 B2.8%
2020-12-31NZ$208.67 B57.7%
2019-12-31NZ$132.32 B49.54%
2018-12-31NZ$88.48 B-11.22%
2017-12-31NZ$99.67 B4.45%
2016-12-31NZ$95.42 B23.11%
2015-12-31NZ$77.51 B120.74%
2014-12-31NZ$35.11 B-1.17%
2013-12-31NZ$35.53 B8.22%
2012-12-31NZ$32.83 B31.26%
2011-12-31NZ$25.01 B-8.7%
2010-12-31NZ$27.39 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
Pfizer
PFE
NZ$361.31 B 55.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$167.71 B-27.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$198.95 B-14.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$156.03 B-32.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$101.32 B-56.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$50.55 B-78.19%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$142.73 B-38.42%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$198.12 B-14.52%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$7.38 B-96.81%๐Ÿ‡บ๐Ÿ‡ธ USA